[1]周 林,肖 康,夏建辉.八珍汤加减辅助治疗原发性肝癌疗效及对患者外周血Th17/Treg平衡和不良反应的影响[J].陕西中医,2023,(9):1216-1219.[doi:DOI:10.3969/j.issn.1000-7369.2023.09.013]
　ZHOU Lin,XIAO Kang,XIA Jianhui.Effect of modified Bazhen decoction adjuvant therapy on peripheral blood Th17/Treg balance and adverse reactions in patients with primary liver cancer[J].,2023,(9):1216-1219.[doi:DOI:10.3969/j.issn.1000-7369.2023.09.013]
点击复制

八珍汤加减辅助治疗原发性肝癌疗效及对患者外周血Th17/Treg平衡和不良反应的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年9期
页码:
1216-1219
栏目:
临床研究
出版日期:
2023-09-05

文章信息/Info

Title:
Effect of modified Bazhen decoction adjuvant therapy on peripheral blood Th17/Treg balance and adverse reactions in patients with primary liver cancer
作者:
周 林; 肖 康; 夏建辉
(庐江县中医院肿瘤二科,安徽 合肥 231500)
Author(s):
ZHOU Lin; XIAO Kang; XIA Jianhui
(The Second Department of Oncology,Lujiang County Hospital of Traditional Chinese Medicine,Hefei 231500,China)
关键词:
原发性肝癌;  八珍汤;  外周血;  辅助性T细胞;  调节性T细胞;  不良反应
Keywords:
Primary liver cancer;  Bazhen decoction;  Peripheral blood;  Helper T cell;  Regulatory T cell;  Adverse reaction
分类号:
R 735.7
DOI:
DOI:10.3969/j.issn.1000-7369.2023.09.013
文献标志码:
A
摘要:
目的:探讨八珍汤加减辅助治疗对原发性肝癌患者外周血辅助性T细胞17/调节性T细胞(Th17/Treg)平衡和不良反应的影响。方法:选择原发性肝癌患者60例,随机分为对照组(n=31)与观察组(n=29)。对照组予以常规肝动脉化疗栓塞术,观察组辅以八珍汤加减治疗。分析两组临床疗效,比较两组治疗前、后中医症候积分、肝功能[天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)、总胆红素(TBIL)],免疫细胞[辅助性T细胞17(Th17)、调节性T细胞(Treg)、Th17/Treg]水平,记录两组不良反应发生率。结果:治疗后,两组总有效率分别为96.55%、80.65%,差异无统计学意义(P>0.05); 两组中医症候积分、AST、ALT、TBIL均降低,但观察组变化幅度更大(P<0.05); 观察组Th17、Treg、Th17/Treg明显低于对照组(P<0.05)。观察组不良反应发生率为6.90%低于对照组的29.03%,差异有统计学意义(P<0.05)。结论:对原发性肝癌患者运用八珍汤加减辅助治疗可有效减轻临床症状,改善患者肝功能,调节机体免疫功能,降低不良反应发生率。
Abstract:
Objective:To investigate the effect of modified Bazhen decoction adjuvant therapy on peripheral blood T helper 17/regulatory T cell(Th17/Treg)balance and adverse reactions in patients with primary liver cancer.Methods:A total of 60 patients with primary liver cancer were selected and assigned to a control group(31 cases)and an observation group(29 cases)by random number table method.Patients in the control group were treated with conventional transcatheter arterial chemoembolization,and patients in the observation group were treated with modified Bazhen decoction on this basis.Clinical effects in the two groups were analyzed.TCM symptom scores,liver function [aspartate aminotransferase(AST),alanine aminotransferase(ALT)and total bilirubin(TBIL)],and immune cells [T helper 17 cells(Th17),regulatory T cells(Treg)and Th17/Treg] were compared between the groups.Adverse reactions in the two groups were recorded.Results:The total effective rates in the two groups were 96.55% and 80.65%(P>0.05).After treatment,TCM symptom scores,the levels of AST,ALT and TBIL in the two groups were decreased.The changes were greater in the observation group(P<0.05).The levels of Th17,Treg and Th17/Treg in the observation group were significantly lower than those in the control group.The incidence rates of adverse reactions in the two groups were 29.03% and 6.90%(P>0.05).Conclusion:Modified Bazhen decoction adjuvant therapy can effectively relieve clinical symptoms,improve liver function,regulate immune function,and reduce the incidence of adverse reactions in patients with primary liver cancer.

参考文献/References:

[1] 李 丹,赵 飞,王树庚.疏肝健脾散结汤联合肝动脉插管化疗栓塞术治疗原发性肝癌疗效研究[J].陕西中医,2021,42(6):728-731.
[2] 方 良,林祖庆.八珍汤合化积丸加减结合肝动脉化疗栓塞术治疗中晚期原发性肝癌临床研究[J].新中医,2020,52(18):57-59.
[3] 马 明,牛婷婷,邵 亮,等.肝动脉化疗栓塞术联合立体定向放疗治疗较大原发性肝癌临床研究[J].创伤与急危重病医学,2017,5(1):32-35.
[4] 李 文,易爱芬,毋 玥.柔肝化纤解毒方辅助治疗对原发性肝癌患者经导管动脉栓塞化疗术后中医证候及肝功能的影响[J].癌症进展,2022,20(8):859-861,864.
[5] 张贵松,刘福军,李风雷,等.中药辅助治疗对原发性肝癌患者行动脉栓塞术后免疫系统及并发症的影响研究[J].四川中医,2017,35(2):96-98.
[6] 白 璐,苏 锐,权兴苗,等.八珍汤加减对胃癌新辅助化疗患者营养状况和免疫功能的影响[J].中国实验方剂学杂志,2021,27(11):117-122.
[7] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J].中华消化外科杂志,2020,19(1):1-20.
[8] 白小林.现代中医内科学[M].长春:吉林科学技术出版社,2012:345-349.
[9] Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours:Revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
[10] 国家中医药管理局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:233-383.
[11] Yu J,Lee SJ,Lee j,et al.Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma[J].Cancer Med,2019,8(16):6986-6994.
[12] 陈百颖,黄 挺,卢晓峰.茵虎汤辅助治疗中晚期原发性肝癌疗效观察及对患者近期生存率的影响[J].中国药物与临床,2019,19(19):3321-3322.
[13] 刘扬河,龙登毅,陈建军.清营活血汤治疗原发性胆汁性肝硬化肝胆湿热型的疗效及对外周血Th17/Treg平衡的影响[J].现代中西医结合杂志,2018,27(21):2356-2359.
[14] 刘云鹤,蔡金保,王红丽.党参多糖抑制PI3K/AKT通路对人肝癌HepG2细胞生长和运动能力的影响[J].中国免疫学杂志,2020,36(9):1108-1113.
[15] Mou HJ,Wu S,Zhao G,et al.Changes of Th17/Treg ratio in the transition of chronic hepatitis B to liver cirrhosis and correlations with liver function and inflammation[J].Exp Ther Med,2019,17(4):2963-2968.
[16] 刘慧敏,刘晓利,王欣惠,等.原发性肝癌患者外周血CD4+T、CD8+T、Tc17、Th17和Treg淋巴细胞的变化及其意义[J].实用肝脏病杂志,2022,25(2):255-258.
[17] 牛占恩,井大新,许崇艳.八珍汤加减方结合化疗方案序贯治疗气阴两虚型急性淋巴细胞白血病患者的临床疗效分析[J].中国实验血液学杂志,2022,30(1):119-125.
[18] 李会杰,郑五州,郭亚南,等.柔肝化纤解毒方联合肝动脉化疗栓塞术治疗肝癌肝肾阴虚证的疗效及对肝纤维化指标的影响[J].世界中西医结合杂志,2022,17(5):973-977.
[19] 陶 琳.原发性肝癌患者化疗后抗菌药物的应用及继发感染的危险因素分析[J].陕西医学杂志,2023,52(1):89-92.
[20] 徐 珊,裴巧丽,杜东青,等.加味八珍汤联合化疗对子宫内膜癌患者T细胞亚群水平、止痛效果及生存质量的影响[J].海南医学,2021,32(1):22-25.

相似文献/References:

[1]乔喜婷,王 昊△,杨 林,等.复元活血汤合化积丸联合肝动脉栓塞化疗术治疗原发性肝癌临床研究*[J].陕西中医,2019,(8):998.
　QIAO Xiting,WANG Hao,YANG Lin,et al.Fuyuan Huoxue decoction plus Huaji pills and hepatic artery embolization in the treatment of primary liver cancer[J].,2019,(9):998.
[2]李 丹,赵 飞,王树庚.疏肝健脾散结汤联合肝动脉插管化疗栓塞术治疗原发性肝癌疗效研究[J].陕西中医,2021,(6):728.[doi:DOI:10.3969/j.issn.1000-7369.2020.06.012]
　LI Dan,ZHAO Fei,WANG Shugeng.Effect of Shugan Jianpi Sanjie decoction combined with transcatheter arterial chemoembolization in the treatment of primary liver cancer[J].,2021,(9):728.[doi:DOI:10.3969/j.issn.1000-7369.2020.06.012]
[3]赵培西,许建秦,袁 彬,等.扶正抗癌方治疗肝癌肝郁脾虚瘀毒证临床研究[J].陕西中医,2022,(12):1746.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.022]
[4]徐巧笑,胡振斌,莫莎莎,等.从“虚、毒、瘀”浅谈原发性肝癌病机和治疗[J].陕西中医,2023,(10):1431.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.022]
　XU Qiaoxiao,HU Zhenbin,MO Shasha,et al.Discussion on pathogenesis and treatment of primary liver cancer from the perspective of “deficiency,poison,and blood stasis”[J].,2023,(9):1431.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.022]
[5]吉 银,戴 铭,王振常,等.逍遥散合大黄虫丸治疗原发性肝癌经肝动脉化疗栓塞术后气滞血瘀型疗效研究[J].陕西中医,2024,(2):187.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.008]
　JI Yin,DAI Ming,WANG Zhenchang,et al.Treatment of primary hepatocellular carcinoma qi stagnation and blood stasis type patients after TACE with Xiaoyao San combined with Dahuang Zhechong pill[J].,2024,(9):187.[doi:DOI:10.3969/j.issn.1000-7369.2024.02.008]
[6]李俊漪,徐 剑.龙胆泻肝汤对原发性肝癌肝动脉栓塞化疗术后患者肝功能及肿瘤标志物的影响研究[J].陕西中医,2024,(10):1353.[doi:DOI:10.3969/j.issn.1000-7369.2024.10.012]
　LI Junyi,XU Jian.Longdan Xiegan decoction on liver function and tumor markers in patients with PHC after TACE[J].,2024,(9):1353.[doi:DOI:10.3969/j.issn.1000-7369.2024.10.012]
[7]曹虹丽,彭廷云,陈青山,等.柴芍六君子汤对原发性肝癌患者化疗期间疗效及免疫功能的影响[J].陕西中医,2024,(11):1495.[doi:DOI:10.3969/j.issn.1000-7369.2024.11.011]
　CAO Hongli,PENG Yanyun,CHEN Qingshan,et al.Effect of Chaishao Liujunzi decoction on therapeutic effect and immune function of primary liver cancer during chemotherapy[J].,2024,(9):1495.[doi:DOI:10.3969/j.issn.1000-7369.2024.11.011]

备注/Memo

备注/Memo:
基金项目:安徽省科技攻关项目(2004H08020246)
更新日期/Last Update: 2023-09-08